anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Thl type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
Panelists will be screened for their ability to discriminate 0.5% linoleic acid emulsion from the blank using two sequential tetrad tests. Panelists will wear nose clips during the tests. Panelists must successfully complete both tetrads in order to qualify for the study. Panelists who qualify for the full study will provide written informed consent as well as data on their ethnic background, age, and their habitual fat intake. Heights and weights will be measured.

After completing the screening tests and the demographic questions, panelists will receive 15 samples (for the first group: "All tastes sorting") or 12 samples (for the second group: "Bitters sorting"). When panelists receive the samples, they will be instructed to put on nose clips and keep the clips on for the duration of the test. Participants will be provided with water for rinsing their mouths as well as a cup to spit the samples into after tasting. Panelists will be provided with more water and additional spit cups as necessary. Next, panelists will be instructed to: "Taste each sample, spit it into the spit cup, and rinse with water. Then, sort the samples into groups you believe are similar. Groups may contain as many or as few samples as you desire. You may have as many or as few groups as you desire." Once they have decided on their groups, they will write in a description for each group and rate the group for its overall similarity. After finishing this initial sorting task, if panelists have more than two total groups, they will be instructed to select the two groups they believe are most similar to each other and combine them. If panelists still have more than two total groups, they will be instructed to combine the two most similar groups again. This will continue until panelists only have two groups remaining. At each level, panelists will rate the new, combined group for its overall similarity on a visual analog scale, as before.

Data from this sorting task will be compiled in to dissimilarity matrices for each participant, showing how many groups it took them before each sample was combined with each other sample. This data will be analyzed to determine if the fatty acid samples are similar or unique in sensation from other taste qualities.
The importance of good sleep has been gaining interest in critically ill patients as poor sleep has been found to be associated with increased rates of delirium, non-invasive ventilation failure, and may serve as a stressor to patients. The use of earplugs and eye masks to improve sleep quality has been described in the critically ill patient population and outcomes have suggested that such interventions have resulted in longer sleep time and Rapid Eye Movement sleep, shorter sleep onset latency and less awakenings, with an enhanced perceived sleep quality. In the post-anaesthesia care unit, these interventions have also led to significantly preserved sleep quality in patients. The primary outcome of this randomized control trial is to evaluate if the use of eye masks and earplugs in patients undergoing major abdominal surgery, and who will be admitted to a monitored unit postoperatively, will lead to improved sleep quality. Secondary outcomes evaluated include the level of noise intensity in the various monitored units (Intensive Care Unit/Intermediate Care Area/High Dependency Ward), incidence of delirium, nursing demand, length of hospitalization and anaesthetic techniques. With these findings, we hope to be able to improve patients' overall satisfaction with the healthcare received.
FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
The present disclosure provides compositions and methods for targeting EGFR antigens to, for example, treat or manage cancer. Provided compositions include binding proteins that are capable of binding to an EGFR antigen : HLA complex. Binding proteins include, for example, T cell receptors, fragments thereof, and chimeric antigen receptors. Also provided are polynucleotides and vectors encoding binding proteins. Disclosed polynucleotides and vectors can be introduced into an immune cell, such as a T cell, and used in immunotherapy in a subject having or at risk for a cancer associated with EGFR expression or activity. The present disclosure also provides immunogenic compositions comprising EGFR antigens, and related uses.
The use of meloxicam for the treatment of the signs and symptoms of osteoarthritis of the knee and hip was evaluated in a 12-week, double-blind, controlled trial. Meloxicam (3.75 mg, 7.5 mg, and 15 mg daily) was compared to placebo. The four primary endpoints were investigator’s global assessment, patient global assessment, patient pain assessment, and total WOMAC score (a self-administered questionnaire addressing pain, function, and stiffness). Patients on meloxicam 7.5 mg daily and meloxicam 15 mg daily showed significant improvement in each of these endpoints compared with placebo. 

The use of meloxicam for the management of signs and symptoms of osteoarthritis was evaluated in six double-blind, active-controlled trials outside the U.S. ranging from 4 weeks’ to 6 months’ duration. In these trials, the efficacy of meloxicam, in doses of 7.5 mg/day and 15 mg/day, was comparable to piroxicam 20 mg/day and diclofenac SR 100 mg/day and consistent with the efficacy seen in the U.S. trial. 

The use of meloxicam for the treatment of the signs and symptoms of rheumatoid arthritis was evaluated in a 12-week, double-blind, controlled multinational trial. Meloxicam (7.5 mg, 15 mg, and 22.5 mg daily) was compared to placebo. The primary endpoint in this study was the ACR20 response rate, a composite measure of clinical, laboratory, and functional measures of RA response. Patients receiving meloxicam 7.5 mg and 15 mg daily showed significant improvement in the primary endpoint compared with placebo. No incremental benefit was observed with the 22.5 mg dose compared to the 15 mg dose.
The invention discloses a Chinese herbal whitening composition, a facial mask and a preparation method of the facial mask. The Chinese herbal composition comprises the following main components: pearl, borax, amber, aloe powder, panthenol, nutmeg kernel oil, trehalose, a sargassum fusiforme extract, a safflower extract, a licorice root extract, a tribulus terrestris fruit extract, a paeonia suffruticosa root extract, an extract of the root and stem/ root of medicinal solomonseal rhizome and zinc carbonate hydroxide. A mask pasting carrier is soaked into a herbal liquid of the Chinese herbal composition so as to form a facial whitening mask. The main components in the formula are prepared by virtue of a Chinese herb superfine pulverizing technology, so that the Chinese herbs are micronized and can easily penetrate through the mucosa of skin. Thus, the whitening effect is obvious after the facial whitening mask is used. The facial whitening mask has good abilities of inhibiting melanin and increasing skin brightness and a good moisture preserving effect, and has a strong moisturizing effect and a persistent water locking effect. Meanwhile, the facial whitening mask is safe and non-irritant and cannot perform an adverse reaction on a human body.
Fractures around the distal humerus fractures make up to 2% of all fractures. Complex intra-articular distal humerus fractures present as challenge to restore of painless, stable and mobile elbow joint. Surgical exposure to all critical structures is of paramount importance to achieve anatomic reduction. Conflict still persists regarding the choice of ideal approach between triceps-sparing approach compared with olecranon osteotomy approach. In this study investigators compare the effect of surgical approach triceps lifting vs olecranon osteotomy on the functional outcome after fixation of distal humerus intra-articular fractures. Investigators conducted a non-funded, non-commercial, retrospective cohort study on participants with closed distal humerus intra-articular fractures between 2010 and 2015 at our tertiary care level-1 trauma and university hospital. Participants \>18 years of age with closed complex intra-articular distal humerus fracture were operated using two different surgical approaches, either triceps lifting approach (Group1) or with olecranon osteotomy (Group 2). Functional evaluation of the participant is carried out with quick DASH scores at the final 1 year follow-up. Investigators concluded that triceps lifting approach can be used equally efficiently for exposure of these complex distal humerus injuries with no comprise in visibility of articular fragments.
PURPOSE:To prevent the damage of the hair and to sustain a permanent treatment over a long period by putting a treatment agent into which protein to prevent runoff into the hair cortex is incorporated into a dissolved state and penetrating the agent into the hair, then applying the treatment agent for protection on the surface of the hair and making operation by using a hair iron. CONSTITUTION:The hair is subjected to the conventional operation method and is simultaneously heated by a steamer. The set temp. of the steamer is about 50 deg.C and the heating time is set at about 15 to 20 minutes. The treatment agent contg. the protein to prevent the runoff is applied on the surface of the hair, by which the protein to prevent the runoff is dissolved and penetrated in place of the mesenchymal material. The treatment agent for protecting the hair iron is then applied on the surface of the hair and the hair is permed by the heat of the hair iron. The chemical change by the high heat of the hair iron is applied to the protein penetrated into the hair cortex in such a manner, by which the protein is thermally solidified and the elution thereof is prevented.
BACKGROUND: Acute kidney injury (AKI) is one of the most common complications for critically ill patients with cirrhosis, but it has remained unclear whether urine output fluctuations are associated with the risk of AKI in such patients. Thus, we explored the influence of 24-h urine-output trajectory on AKI in patients with cirrhosis through latent category trajectory modeling.
MATERIALS AND METHODS: This retrospective cohort study examined patients with cirrhosis using the MIMIC-IV database. Changes in the trajectories of urine output within 24 h after admission to the intensive care unit (ICU) were categorized using latent category trajectory modeling. The outcome examined was the occurrence of AKI during ICU hospitalization. The risk of AKI in patients with different trajectory classes was explored using the cumulative incidence function (CIF) and the Fine-Gray model with the sub-distribution hazard ratio (SHR) and the 95% confidence interval (CI) as size effects.
RESULTS: The study included 3,562 critically ill patients with cirrhosis, of which 2,467 (69.26%) developed AKI during ICU hospitalization. The 24-h urine-output trajectories were split into five classes (Classes 1-5). The CIF curves demonstrated that patients with continuously low urine output (Class 2), a rapid decline in urine output after initially high levels (Class 3), and urine output that decreased slowly and then stabilized at a lower level (Class 4) were at higher risk for AKI than those with consistently moderate urine output (Class 1). After fully adjusting for various confounders, Classes 2, 3, and 4 were associated with a higher risk of AKI compared with Class 1, and the respective SHRs (95% CIs) were 2.56 (1.87-3.51), 1.86 (1.34-2.59), and 1.83 1.29-2.59).
CONCLUSIONS: The 24-h urine-output trajectory is significantly associated with the risk of AKI in critically ill patients with cirrhosis. More attention should be paid to the dynamic nature of urine-output changes over time, which may help guide early intervention and improve patients' prognoses.
Described embodiments include a system, method, and computer program product. A described system includes a receiver circuit that receives a first reference image that includes an objective landmark subsurface feature of a mammalian body part, and receives a second reference image that includes a present-location landmark subsurface feature of the mammalian body part. The objective landmark subsurface feature has a first spatial relationship to a destination region of interest of the mammalian body part. The present-location landmark subsurface feature has a second spatial relationship to a distal end portion of a body-insertable device. The system includes a feature matching circuit that determines a substantial correspondence between the present-location landmark subsurface feature and the objective landmark subsurface feature. The system includes a proximity indicator circuit that generates informational data indicative of an operational proximity of the distal end portion of the body-insertable device to the destination region of interest.
Systems, methods, and apparatuses for verifying and performing operations on homomorphic encrypted data are described herein. The method includes securely transmitting encrypted data without completely decrypting the data and extracting information from the data. The data request may include an encrypted portion that includes a set of confidential data. One or more sets of encrypted comparison data may then be retrieved from the database in response to the data request. The set of encrypted secret data from the data request is then compared to each set of encrypted comparison data using one or more homomorphic operations to determine which set of encrypted comparison data matches the set of encrypted secret data. If there is a match, the set of secret data is verified. An encryption indicator is then generated indicating success or failure to verify the set of secret data, which may then be forwarded to a party associated with the data request.
BACKGROUND/AIM: Adjuvant capecitabine and oxaliplatin (CAPOX) therapy is standard strategy for colorectal cancer with risk of recurrence. Early dose reduction (EDR) of CAPOX therapy is commonly used in real-world practice. However, there is limited evidence regarding the effectiveness of CAPOX for patients who had EDR. Therefore, this study aimed to clarify the risks of EDR and its effect on long-term outcomes and body composition factors.
PATIENTS AND METHODS: Patients who received CAPOX therapy after radical surgery for colorectal cancer between June 2013 and December 2021 were included. EDR was defined as dose reduction within four courses of CAPOX therapy. Body composition factors were measured for 1 year following surgery to determine the EDR effects.
RESULTS: Eighty-four patients were included; 35 (42%) of them had EDR. The multivariate analysis revealed that underweight [odds ratio (OR)=4.95, 95% confidence interval (CI)=1.13-21.7, p=0.03] was a risk factor for EDR. Relapse-free survival (RFS) was significantly better in the non-EDR group (p=0.01). The 5-year RFS rates for the non-EDR and EDR groups were 88.7% and 65.4%, respectively. The multivariate analysis revealed that age >65 years [hazard ratio (HR)=3.97; 95% CI=1.16-13.62, p=0.03] and EDR (HR=7.62; 95% CI=1.71-33.91, p=0.005) were associated with poorer RFS. The 1-year body composition analysis revealed decreases in all factors in the EDR group.
CONCLUSION: Preoperative underweight status was associated with EDR, which resulted in decreased RFS and body composition factors when compared with the non-EDR group. Therefore, avoiding EDR and early nutritional intervention after EDR may improve outcomes.
Provided is a novel  Lactobacillus fermentum  strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A  Lactobacillus fermentum  according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the  Lactobacillus fermentum  may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The  Lactobacillus fermentum  strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The  Lactobacillus fermentum  strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the  Lactobacillus fermentum  strain may be usefully used to prevent or treat a metabolic disease such as obesity.
The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration "sham" and 5 minutes of slowdown. The vibration sham; will be held with the disconnected platform. A device will be connected producing a noise similar to the sound of the connected platform for a time equivalent to the treatment protocol, since it will not be possible to distinguishing noticeably stimulate vibrator. Participants that will undergo false vibration will not have contact with those who carry out the real treatment.
Fine particulate matter (PM2.5) is an air pollutant that enhances susceptibility to cardiovascular diseases. Macrophages are the first immune cells to encounter the inhaled particles and orchestrate an inflammatory response. Given their role in atherosclerosis development, we investigated whether aqueous PM2.5 could elicit atherogenic effects by polarising macrophages to a pro-oxidative and pro-inflammatory phenotype and enhancing foam cell formation. The RAW264.7 macrophage cell line was exposed to PM2.5 for 48 h, with PBS as the control. Aqueous PM2.5 induced apoptosis and reduced cell proliferation. In surviving cells, we observed morphological, phagocytic, oxidative, and inflammatory features (i.e. enhanced iNOS, Integrin-1β, IL-6 expression), indicative of classical macrophage activation. We also detected an increase in total and surface HSP70 levels, suggesting macrophage activation. Further, exposure of high-cholesterol diet-fed mice to PM2.5 resulted in aortic wall enlargement, indicating vascular lesions. Macrophages exposed to PM2.5 and non-modified low-density lipoprotein (LDL) showed exacerbated lipid accumulation. Given the non-oxidised LDL used and the evidence linking inflammation to disrupted cholesterol negative feedback, we hypothesise that PM2.5-induced inflammation in macrophages enhances their susceptibility to transforming into foam cells. Finally, our results indicate that exposure to aqueous PM2.5 promotes classical macrophage activation, marked by increased HSP70 expression and that it potentially contributes to atherosclerosis.
Compositions and methods for the administration of active agents are generally described. In some embodiments, compositions comprising peptide moieties are described. The peptide moieties may comprise sodium channel peptide sequences, such as TQDYWEN (SEQ ID NO: 1) and/or CGEWIET (SEQ ID NO: 2). According to certain embodiments, the peptide moieties are connected to a hydrophobic domain. The presence of both the peptide moiety and the hydrophobic domain may drive self-assembly (e.g., to form a supramolecular nanostructure). The supramolecular nanostructure may facilitate cooperative interaction between distinct peptide sequences. In some embodiments, the peptide sequences bind to the active agents. Binding between the active agent and the peptide sequences may advantageously facilitate controlled release of the active agent. In the context of the present disclosure, it has been inventively recognized that drug delivery may be improved through the use of compositions and methods described herein below.
The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. A regimen of 20 mg b.i.d. is also effective. Acute Therapy:

The recommended adult oral dose is 20 mg once a day at bedtime. Maintenance Therapy:
BACKGROUND: The relationship of inflammatory bowel disease (IBD) with osteonecrosis or avascular necrosis (AVN) is uncertain.
METHODS: Systematic review to estimate the frequency of osteonecrosis in IBD was performed. Electronic databases were searched on 12 December 2022 to identify relevant studies. We planned to estimate the pooled prevalence of AVN in IBD, the risk in IBD when compared to the healthy population (without any chronic disease), and the impact of steroid use on osteonecrosis (IBD with and without steroid use). The risk of Bias was assessed with the Joanna Briggs Institute appraisal tool.
RESULTS: Fifteen studies including 105 154 individuals were included. The pooled rate AVN was 10.39 per 1000 patients (95% confidence interval, 4.44-24.11, I 2  = 97%). Subgroup analysis suggested that the prevalence was lower in larger studies (>1000 participants) at 3.10, 1.07; 8.98, I 2  = 98% versus 21.03, 8.69; 50.01, I 2  = 83%. The use of steroids did not seem to increase the risk of osteonecrosis in the included studies (pooled odds ratio: 1.88, 0.55-6.41, I 2  = 39%). The systematic review was limited by the absence of comparison with the control population free of chronic disease.
CONCLUSION: IBD may be associated with a risk of osteonecrosis. Future studies should assess the risk in comparison to the healthy population and the impact of disease activity and IBD therapies on the risk.
An astringent hemostatic composition comprised of a micron-sized astringent hemostatic agent microencapsulated in a biocompatible and non-allergenic hemostatic polymer soluble in body fluids. The composition may be used intraorally or dermatologically. For intraoral purposes, the preferred composition is ferric sulfate microencapsulated in ethyl cellulose material. The composition of the invention may be used in a method for effecting gingival retraction. In the method, the microencapsulated astringent hemostatic composition is introduced into the gingival sulcus and is compacted by the patient biting onto bite registration material. A plurality of different microencapsulated astringent hemostatic agents having different time-release properties may be assembled in a kit form allowing a practitioner to formulate a specific formulation designed to treat a specific injury or condition. 
     An astringent hemostatic composition of the invention may be used in a bandage for covering a wound. In one bandage embodiment, the gauze or sponge pad is sprayed with a biocompatible adhesive onto which a dusting of astringent hemostatic composition of the invention is applied. In a second bandage embodiment, a layer or dusting of astringent hemostatic composition of the invention is sandwiched between an upper and lower gauze or sponge layer. In a third bandage embodiment, an astringent hemostatic composition of the invention is adhered to a transdermal bandage using a biocompatible adhesive.